Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Griffith

Showing results (251-260 of 512) with videos related to

Pageof 52
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2006
TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T cellsVladimir P Badovinac, Kelly A Nordyke Messingham, Thomas S Griffith, et al.
Expert Reviews in Molecular Medicine|March 27, 2014
GLP-1-mediated gene therapy approaches for diabetes treatmentMukerrem Hale Tasyurek, Hasan Ali Altunbas, Halit Canatan, et al.
Clinical Pharmacology and Therapeutics|November 1, 1982
Suppression of complex ventricular arrhythmias by oral flecainideD Duran, E V Platia, L S Griffith, et al.
Human Gene Therapy|April 16, 2021
Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for VaccinationAtil Bisgin, Ahter D Sanlioglu, Yunus Emre Eksi, et al.
Cancer Gene Therapy|September 15, 2007
DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cellsA D Sanlioglu, B Karacay, I T Koksal, et al.
Journal of Molecular Endocrinology|September 20, 2012
Therapeutic potential of VIP vs PACAP in diabetesAhter D Sanlioglu, Bahri Karacay, Mustafa Kemal Balci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2008
CD8 T cells utilize TRAIL to control influenza virus infectionErik L Brincks, Arna Katewa, Tamara A Kucaba, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1980
Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drugD S Alberts, K S Griffith, G E Goodman, et al.
ACS Applied Materials & Interfaces|November 16, 2010
Hybrid inorganic-organic adsorbents Part 1: Synthesis and characterization of mesoporous zirconium titanate frameworks containing coordinating organic functionalitiesChristopher S Griffith, Massey De Los Reyes, Nicholas Scales, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 21, 2010
Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cellsThomas S Griffith, Erik L Brincks, Prajwal Gurung, et al.
Pageof 52

Showing results (251-260 of 512) with videos related to

Sort By:
Pageof 52
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2006
TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T cellsVladimir P Badovinac, Kelly A Nordyke Messingham, Thomas S Griffith, et al.
Expert Reviews in Molecular Medicine|March 27, 2014
GLP-1-mediated gene therapy approaches for diabetes treatmentMukerrem Hale Tasyurek, Hasan Ali Altunbas, Halit Canatan, et al.
Clinical Pharmacology and Therapeutics|November 1, 1982
Suppression of complex ventricular arrhythmias by oral flecainideD Duran, E V Platia, L S Griffith, et al.
Human Gene Therapy|April 16, 2021
Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for VaccinationAtil Bisgin, Ahter D Sanlioglu, Yunus Emre Eksi, et al.
Cancer Gene Therapy|September 15, 2007
DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cellsA D Sanlioglu, B Karacay, I T Koksal, et al.
Journal of Molecular Endocrinology|September 20, 2012
Therapeutic potential of VIP vs PACAP in diabetesAhter D Sanlioglu, Bahri Karacay, Mustafa Kemal Balci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2008
CD8 T cells utilize TRAIL to control influenza virus infectionErik L Brincks, Arna Katewa, Tamara A Kucaba, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1980
Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drugD S Alberts, K S Griffith, G E Goodman, et al.
ACS Applied Materials & Interfaces|November 16, 2010
Hybrid inorganic-organic adsorbents Part 1: Synthesis and characterization of mesoporous zirconium titanate frameworks containing coordinating organic functionalitiesChristopher S Griffith, Massey De Los Reyes, Nicholas Scales, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 21, 2010
Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cellsThomas S Griffith, Erik L Brincks, Prajwal Gurung, et al.
Pageof 52